- Home
- ALXO vs YSXT Comparison
ALXO vs YSXT Comparison
Compare ALXO & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALXO | YSXT |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Automotive Aftermarket |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 58.6M |
| IPO Year | 2020 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ALXO | YSXT |
|---|---|---|
| Price | $1.50 | $1.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $3.30 | N/A |
| AVG Volume (30 Days) | 268.8K | ★ 780.1K |
| Earning Date | 11-07-2025 | 07-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $71,452,736.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.80 |
| Revenue Growth | N/A | ★ 22.04 |
| 52 Week Low | $0.40 | $1.25 |
| 52 Week High | $2.27 | $9.96 |
Technical Indicators
Market Signals| Indicator | ALXO | YSXT |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 40.77 |
| Support Level | $1.29 | $1.25 |
| Resistance Level | $1.57 | $2.45 |
| Average True Range (ATR) | 0.11 | 0.32 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 76.25 | 44.58 |
Price Performance
Historical ComparisonAbout ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.